Calcium Dobesilate Tablets & Capsules Suppliers & Bulk Manufacturers
Available Forms: Tablets & Capsules
Available Strengths: 250 mg & 500 mg
Reference Brands: Doxium®, Doxium MADAUS® (EU)
Category:
Diabetes
Calcium Dobesilate improves microcirculation by reducing capillary permeability and enhancing vascular resistance. It stabilizes endothelial function, inhibits platelet aggregation, and decreases blood viscosity. Clinically, it benefits patients with diabetic retinopathy, chronic venous insufficiency, and hemorrhoids by improving blood flow, reducing edema, and preventing microvascular complications in chronic vascular conditions.
Calcium Dobesilate Tablets & Capsules is available in Tablets & Capsules
and strengths such as 250 mg & 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Calcium Dobesilate Tablets & Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Calcium Dobesilate Tablets & Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Calcium Dobesilate is primarily approved and marketed in the European Union and several other countries but is not FDA-approved in the United States. It is widely prescribed in the EU under brand names like Doxium® for the treatment of chronic venous insufficiency, diabetic retinopathy, and hemorrhoidal disease. The drug is classified as a vasoprotective agent with angioprotective and anti-inflammatory effects. Regulatory bodies in the EU consider it safe and effective when prescribed appropriately, although it is not included in U.S. pharmacotherapy due to lack of FDA approval. Physicians in the EU continue to favor it for vascular and retinal microcirculation support.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing